FIGURE 2:

Statin-mediated reduction in Aβ secretion is Tau-independent. (A) We used CRISPR/Cas9 to create MAPT KO iPSC lines by creating an insertion-induced stop codon at the MAPT locus. (B) Western blot confirming knockout of Tau protein in the MAPT KO iPSC lines. (C) WT and MAPT KO iPSCs were differentiated to neurons and then fixed, permeabilized, stained for MAP2 (neuron cell body marker), and then imaged. WT and MAPT KO lines both differentiate to MAP2-positive neurons with similar neuronal morphologies. (D, E) WT or Tau KO neurons were treated with DMSO or 10 μM atorvastatin or simvastatin for 5 d. (D) Aβ42 levels and (E) Aβ40 levels were determined by MSD-ECL (mean ± SEM, n ≥ 3).